from these data , an adequate inhibition of peripheral decarboxylation and hence a good bioavailability of levodopa may be expected in patients taking low doses of carbidopa-levodopa , using currently available commercial preparations .
C0023570
levodopa
C0353697
carbidopa-levodopa